Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The standard or usual treatment for this disease is pembrolizumab given by needle every three weeks. This study will be done in two stages. The purpose of stage 1 of the study is to find out if we can use blood tests to see how the cancer is responding to treatment with pembrolizumab. A second stage...
The standard or usual treatment for this disease is pembrolizumab given by needle every three weeks. This study will be done in two stages. The purpose of stage 1 of the study is to find out if we can use blood tests to see how the cancer is responding to treatment with pembrolizumab. A second stage of the study will take place once stage 1 is completed. In stage 2 blood tests will be used to help determine if patients whose cancer does not seem to be getting better on treatment with pembrolizumab, would do better on a different treatment.
Tracking Information
- NCT #
- NCT04093167
- Collaborators
- Cancer Research Institute, New York City
- Personal Genome Diagnostics (PGDx)
- Mark Foundation for Cancer Research
- Investigators
- Study Chair: Valsamo Anagnostou Johns Hopkins University Study Chair: Cheryl Ho BCCA - Vancouver Cancer Centre
Get Well Soon